MedTrace Logo

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

NCT05514444 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-10-09

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of MK-4464 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.

Conditions

  • Advanced/Metastatic Solid Tumors
  • Neoplasms

Interventions

BIOLOGICAL

MK-4464

MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.

BIOLOGICAL

Pembrolizumab

Pembrolizumab 200 mg administered as an IV infusion every three weeks.

DRUG

89Zr-MK-4464

89ZR-MK-4464 administered as an IV infusion on C1D1.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-25
Primary Completion
2025-09-18
Completion
2025-09-18
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Israel
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05514444 on ClinicalTrials.gov